UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

SUMMIT THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

 

 

 

England and Wales   Not Applicable
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

85b Park Drive

Milton Park, Abingdon

Oxfordshire

United Kingdom

+44 1235 443 939

  OX14 4RY
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of each exchange on which

each class is to be registered

American Depositary Shares

each representing five Ordinary Shares

  The NASDAQ Stock Market LLC
Ordinary Shares, par value £0.01 per share   The NASDAQ Stock Market LLC*

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.   x

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.   ¨

Securities Act registration statement file numbers to which this form relates:

333-201807

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent Ordinary Shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6.

 

 

 


Item 1. Description of Registrant’s Securities to be Registered.

Summit Therapeutics plc (the “Registrant”) hereby incorporates by reference (a) the description of its Ordinary Shares, par value £0.01 per share, to be registered hereunder under the heading “Description of Share Capital,” (b) the description of its American Depositary Shares, each representing five Ordinary Shares, to be registered hereunder under the heading “Description of American Depositary Shares” and (c) the information set forth under the heading “Taxation,” in each case, in the Registrant’s Registration Statement on Form F-1 (File No. 333-201807), as originally filed with the Securities and Exchange Commission (the “Commission”) on January 30, 2015, as subsequently amended (the “Registration Statement”), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information shall be deemed to be incorporated by reference herein.

 

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

2


SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

SUMMIT THERAPEUTICS PLC
By:

/s/ Erik Ostrowski

Name: Erik Ostrowski
Title: Chief Financial Officer

Dated: March 2, 2015

 

3